Clinical trials: Urinary Symptoms
Overactive Bladder
Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms
To evaluate the safety and durability of the TheraNova Neuromodulation System in overactive bladder (OAB) patients.
- Trial name
- NCT05162833
- Testing
- TheraNova Neuromodulation Device
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Theranova, L.L.C.
Stress Urinary Incontinence
To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence
The patients are being followed in this study to determine the safety of taking the medication Duloxetine for a long period of time. The patients participating in this study suffer from Stress Urinary Incontinence.
- Trial name
- NCT00190645
- Testing
- Duloxetine
- Where
- 2 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Stress Urinary Incontinence
Virtue® Male Incontinence Sling Study
This study is a multi-center, global study that will assess the effectiveness and patient satisfaction of the male incontinence sling 12 months after implant as well as the safety profile of the product.
- Trial name
- NCT00856778
- Testing
- Virtue® Male Incontinence Sling
- Where
- 11 sites in United States, Canada
- Volunteers
- 98 people
- Sponsor
- Coloplast A/S
LUTS, Benign Prostatic Hyperplasia
Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers
The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.
- Conditions
- LUTS, Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02447367
- Testing
- JLP-1207(Fasted), JLP-1207(Fed)
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Recurrent Cystitis
Comparative Effect of 3 Different Cranberry Extracts on Cystitis Related Urinary Comfort in Women
Urinary discomfort includes a set of signs such as an urgent need to urinate, high frequency of urination per day, discomfort / difficulty or burning sensation when urinating, smelly urine.
- Trial name
- NCT04962971
- Testing
- X, Y, Z
- Where
- France
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- CEN Biotech
Renal Insufficiency
Association Between COVID-19 and UTIs Caused by ESBL Organism in Infants
Urinary tract infections (UTIs) in infants and young children are one of the most common bacterial infections, usually febrile illness without source, frequently due to Enterobacteriaceae, mainly Escherichia coli.
- Trial name
- ABCUCEOI (NCT05630326)
- Testing
- comparing, prevalence, assessment, association
- Where
- Qatar
- Volunteers
- 5,600 people
- Sponsor
- Hamad Medical Corporation
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
The purpose of the study is to evaluate the safety and to define the Maximal Tolerated Dose (MTD) or the Maximal Administered Dose (MAD) of oral azacitidine as a single agent and in combination with carboplatin (CBDCA) or…
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01478685
- Testing
- CC-486, Carboplatin, ABI-007
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 169 people
- Sponsor
- Celgene
Urinary Incontinence, Stress, Intrinsic Sphincter Deficiency
AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up
A single-center retrospective chart review of AdVance and AdVance XP subject data, combined with prospective follow-up of the same subjects to confirm continence, adverse event, and quality of life status.
- Trial name
- NCT01725984
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- American Medical Systems
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- Neptune II (NCT01021332)
- Testing
- tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg), tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
- Where
- 70 sites in Austria, Belarus and 9 more
- Volunteers
- 1,067 people
- Sponsor
- Astellas Pharma Europe B.V.
Overactive Bladder
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron modified release low dose or high dose tablets…
- Trial name
- VEL-2001 (NCT03594058)
- Testing
- Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose
- Where
- 77 sites in United States
- Volunteers
- 1,413 people
- Sponsor
- Velicept Therapeutics, Inc.
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.
- Trial name
- NCT00311376
- Testing
- botulinum toxin Type A (200U), botulinum toxin Type A (300U)
- Where
- 14 sites in United States, Australia and 12 more
- Volunteers
- 416 people
- Sponsor
- Allergan
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Safety and Effectiveness Study of the Zenflow Spring System
Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.
- Trial name
- BREEZE (NCT04987138)
- Testing
- Zenflow Spring System
- Where
- 7 sites in United States
- Volunteers
- 279 people
- Sponsor
- Zenflow, Inc.
Urinary Incontinence, Over Active Bladder
Sacral Neuromodulation With InterStim® Therapy for Intractable Urinary Voiding Dysfunctions (SOUNDS): an Observational Study
The purpose of this study is to document the safety, the effectiveness, the continued performance at mid and long term, the morbidity and the percent of surgical revisions of the Interstim® therapy for up to 5 years in a…
- Conditions
- Urinary Incontinence, Over Active Bladder, Urinary Retention
- Trial name
- SOUNDS (NCT02186041)
- Testing
- Sacral Nerve Modulation
- Where
- 24 sites in France
- Volunteers
- 320 people
- Sponsor
- MedtronicNeuro
Neurogenic Urinary Bladder
Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction
The primary objective of the study was to evaluate the efficacy of Alfuzosin in comparison to Placebo on the detrusor Leak Point Pressure (LPP) in children and adolescents 2-16 years of age with elevated detrusor LPP of…
- Trial name
- ALFACHIN (NCT00549939)
- Testing
- Alfuzosin
- Where
- 18 sites in United States, Bulgaria and 16 more
- Volunteers
- 172 people
- Sponsor
- Sanofi
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00120939
- Testing
- Motexafin Gadolinium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
Urinary Bladder, Neurogenic
Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.
The purpose of this study is to investigate the safety and tolerability of fesoterodine following once daily long-term treatment in Japanese pediatric neurogenic detrusor overactivity (NDO) subjects.
- Trial name
- NCT02501928
- Testing
- Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Fesoterodine BIC 2 mg
- Where
- 7 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Monitoring of the Bladder Filling
inContAlert: Machine Learning Algorithms for Individual Bladder Filling Level Prediction
The aim of this study is to evaluate the bladder filling level of the study participants using the inContAlert sensor. The generated data will be used for the evaluation and optimization of the machine learning algorithms to be…
- Trial name
- NCT05952700
- Testing
- inContAlert
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- inContAlert GmbH
Overactive Bladder
Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer
The primary objective of this study is to evaluate the safety of a single treatment of hMaxi-K compared to placebo (PBS-20% sucrose) administered by direct bladder wall injections.
- Trial name
- OAB (NCT01870037)
- Testing
- hMaxi-K
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder (OAB)
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.
- Trial name
- NCT02294396
- Testing
- Mirabegron tablet, Solifenacin tablet, Propiverine tablet
- Where
- 7 sites in Japan
- Volunteers
- 649 people
- Sponsor
- Astellas Pharma Inc